X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse AJANTA PHARMA with ACTAVIS INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs ACTAVIS (US) - Comparison Results

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 AJANTA PHARMA   ACTAVIS
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
ACTAVIS
Dec-14
AJANTA PHARMA/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs1,72017,418-   
Low Rs1,10310,625-   
Sales per share (Unadj.) Rs194.63,136.6-  
Earnings per share (Unadj.) Rs45.2-391.4-  
Cash flow per share (Unadj.) Rs50.3287.8-  
Dividends per share (Unadj.) Rs8.000-  
Dividend yield (eoy) %0.60-  
Book value per share (Unadj.) Rs132.06,803.1-  
Shares outstanding (eoy) m88.77265.90-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.34.5 162.2%   
Avg P/E ratio x31.2-35.8 -87.1%  
P/CF ratio (eoy) x28.148.7 57.6%  
Price / Book Value ratio x10.72.1 518.7%  
Dividend payout %17.70-   
Avg Mkt Cap Rs m125,2993,728,306 3.4%   
No. of employees `000NA21.6 0.0%   
Total wages/salary Rs m2,5700-   
Avg. sales/employee Rs ThNM38,611.5-  
Avg. wages/employee Rs ThNM0-  
Avg. net profit/employee Rs ThNM-4,818.3-  
INCOME DATA
Net Sales Rs m17,275834,009 2.1%  
Other income Rs m166-2,082 -8.0%   
Total revenues Rs m17,442831,927 2.1%   
Gross profit Rs m5,807107,140 5.4%  
Depreciation Rs m451180,593 0.2%   
Interest Rs m4926,306 0.2%   
Profit before tax Rs m5,474-101,841 -5.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-7,470 0.0%   
Tax Rs m1,460-5,236 -27.9%   
Profit after tax Rs m4,014-104,076 -3.9%  
Gross profit margin %33.612.8 261.7%  
Effective tax rate %26.75.1 518.8%   
Net profit margin %23.2-12.5 -186.2%  
BALANCE SHEET DATA
Current assets Rs m7,639439,416 1.7%   
Current liabilities Rs m2,715320,463 0.8%   
Net working cap to sales %28.514.3 199.8%  
Current ratio x2.81.4 205.2%  
Inventory Days Days4358 74.5%  
Debtors Days Days7966 118.7%  
Net fixed assets Rs m6,914101,841 6.8%   
Share capital Rs m1770-   
"Free" reserves Rs m11,4420-   
Net worth Rs m11,7211,808,934 0.6%   
Long term debt Rs m149947,917 0.0%   
Total assets Rs m14,8143,315,181 0.4%  
Interest coverage x112.9-2.9 -3,933.4%   
Debt to equity ratio x00.5 2.4%  
Sales to assets ratio x1.20.3 463.5%   
Return on assets %27.4-2.3 -1,169.1%  
Return on equity %34.2-5.8 -595.3%  
Return on capital %46.5-3.0 -1,545.4%  
Exports to sales %55.10-   
Imports to sales %6.00-   
Net fx Rs m8,7440-   
CASH FLOW
From Operations Rs m3,264143,216 2.3%  
From Investments Rs m-2,093-342,913 0.6%  
From Financial Activity Rs m-1,186192,667 -0.6%  
Net Cashflow Rs m-15-7,030 0.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 63.85 Rs / USD

Compare AJANTA PHARMA With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare AJANTA PHARMA With: PANACEA BIOTECH  J.B.CHEMICALS  MERCK LTD  NATCO PHARMA  STERLING BIOTECH  



Today's Market

Sensex Trades Strong; Infosys & Axis Bank Top Gainers(01:30 pm)

After opening the day in green, the Indian share markets have continued the momentum and are presently trading on a strong note.

Related Views On News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Is it Wise to Ignore Bitcoins?(The 5 Minute Wrapup)

Jan 4, 2018

While investing in bitcoins, it would make sense to treat it as another asset class and decide accordingly.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Jan 17, 2018 03:07 PM

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 5-YR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS